Insilico Medicine is a clinical-stage, AI-driven drug discovery company. Their pipeline includes several drug candidates targeting conditions such as idiopathic pulmonary fibrosis (IPF) and cancer (Insilico - Pipeline). In July 2023, Insilico announced the initiation of Phase II clinical trials for its lead candidate, Rentosertib (fka ISM001-055), developed using their AI platforms, including Pharma.AI, PandaOmics, and Chemistry42 (Drug Target Review, Cancer.org - Clinical Trials). Please note that this candidate is shown twice, as there are concurrent studies taking place in different parts of the world. Because it is the same molecule/compound being used to treat the same condition, it is only counted once. This question asks participants to forecast how many drug candidates Insilico Medicine will announce as having entered Phase III trials, identified through their AI platforms, as of approximately 5:00p.m. EDT on September 30, 2025. A "novel drug candidate" is defined as a distinct molecule or compound identified using Insilico's AI platforms. The announcement must explicitly state the use of Insilico's AI platforms in the identification process. Acceptable sources include official press releases, the company's website, and credible open-source reporting.

Confused? Check our FAQ or ask us for help. To learn more about Good Judgment and Superforecasting, click here.

To learn more about how you can become a Superforecaster, see here. For other posts from our Insights blog, click here.